Nyschey

05/04/2026

01/01/2026

Happy New Year 2026!

20/04/2025

Wishing you a joyful and prosperous Easter filled with renewal, hope and continued success!

21/03/2025

21/03/2025

We’re excited to announce that NYSCHEY LTD is officially moving into Discovery Park, Kent — one of the UK’s leading science and innovation hubs.

This marks a major milestone for us as we continue to grow and push boundaries in our field. Being part of such a dynamic community opens up incredible opportunities for collaboration, creativity, and innovation.

We’re looking forward to what’s next — and we’re just getting started.

Thanks to Renos Savva and Chris Broom for this opportunity through the Discovery Spark - Oncology Cohort Programme. Wish we met you earlier, but it's never too late. All made possible by good networking.

Also grateful for the support from Barclays Eagle Labs and Andrew Pledger.

08/02/2025

🌟 We are excited to announce that we been selected for the Discovery Spark Program at Discovery Park, Sandwich, Kent! 🎉

This fantastic opportunity will allow us to gain invaluable hands-on experience in the pharmaceutical and life sciences industry, engaging with innovative research and development projects.

At Nyschey, we are committed to fostering the growth of early-career professionals, and we are proud to support our staff as they embark on this incredible journey. We look forward to the new insights and contributions they will bring to the program.

Congratulations, Team Nyschey! We can't wait to see the incredible impact you will make during this experience.

11/07/2023

Molecular glue has emerged as a promising strategy for treating cancer by specifically targeting oncogenic proteins involved in tumor development and progression. These proteins, which are often challenging to target using traditional small-molecule inhibitors, can be selectively bound by molecular glue compounds. Once bound, the molecular glue acts as a bridge, bringing the target protein into proximity with E3 ubiquitin ligases. This leads to the tagging of the protein with ubiquitin and subsequent degradation by the proteasome, effectively eliminating the oncogenic protein from cancer cells. The selectivity of molecular glue compounds allows for precise modulation of cancer-related pathways while minimizing off-target effects. This approach holds potential for overcoming drug resistance and can be used in combination with other cancer therapies to enhance treatment response. Moreover, the personalized nature of molecular glue enables the development of tailored treatments that address the unique molecular drivers of cancer in individual patients. While still in early stages, ongoing research aims to optimize the design and efficacy of molecular glue compounds, paving the way for potential future cancer treatments.

01/01/2023

Welcoming our new AI BioRobots in 2023 🎁🎉

21/06/2022

Vampyrella Amoeba Eating Spirogyra ⁠
⁠
Time-lapse light microscopy footage of a trophozoite (center) attached to and feeding on a strand of (tubular). Vampyrella is a unicellular micro-organism sometimes described as a "vampire amoeba". It attacks other organisms, such as algae, and penetrates their cell walls and extracts the contents (green). The complete process of cell wall pe*******on, suction and extraction is shown in this clip. Vampyrella are found in aquatic freshwater environments, with other vampyrellid species found in soil and in the sea. The speed of this footage has been increased to over 40 times normal.⁠
⁠
Video Source and Credit ©: Thanks to Dr. Oliver Skibbe / Science Source⁠